Mulugeta Russom1, Dawit Tesfai2, Semere Gebregiorgis3, Abdulmumini Usman3, Selam Mihreteab4, Iyassu Bahta5, Elsa Mekonnen6, Selamawit Ghebrehiwet6, Gelila Abrham7. 1. Eritrean Pharmacovigilance Centre, Ministry of Health, P.O. Box: 212, Asmara, Eritrea. satiswt@gmail.com. 2. School of Pharmacy, Asmara College of Health Sciences, Asmara, Eritrea. 3. World Health Organization Country Office, Asmara, Eritrea. 4. National Malaria Control Program, Ministry of Health, Asmara, Eritrea. 5. National Medicines and Food Administration, Ministry of Health, Asmara, Eritrea. 6. Eritrean Pharmacovigilance Centre, Ministry of Health, P.O. Box: 212, Asmara, Eritrea. 7. Tesseney Hospital, Tesseney, Eritrea.
Abstract
INTRODUCTION: Several studies conducted in African countries reported the artesunate and amodiaquine (AS/AQ) tablet as a safe and well-tolerated anti-malarial drug in children and younger adults. The aim of this case series assessment was to assess the causal relationship between the AS/AQ tablet and extrapyramidal reactions in children and younger adults and to investigate the factor(s) predisposing to the adverse drug reactions. METHODS: The causal relationship of all the cases was first assessed individually using the Naranjo Probability Scale and then subjected to a case series assessment using Austin Bradford-Hill criteria. RESULTS: A total of 43 acute extrapyramidal reactions associated with the AS/AQ tablet were reported between 2012 and 16 November, 2015 to the Eritrean Pharmacovigilance Centre. The causality was found to be probable or highly probable for 33 (76.7 %) of the cases and the rest (10; 23.3 %) of the cases had a possible causal association. The extrapyramidal reactions had more or less similar clinical features in most of the cases and were characterized by abnormal involuntary contractions of muscles. The median age and body weight of the cases were 15 years and 40 kg, respectively, and 70 % of them were males. 90.7% of the reactions manifested in children and younger adults (aged <26 years). In most of the cases, reactions manifested in the third day from the start of treatment and 88.3 % of cases were hospitalized. CONCLUSION: The causal relationship between the AS/AQ tablet and extrapyramidal reactions in children and younger adults was found to be apparent and possibly owing to dose accumulation or an overdose of amodiaquine.
INTRODUCTION: Several studies conducted in African countries reported the artesunate and amodiaquine (AS/AQ) tablet as a safe and well-tolerated anti-malarial drug in children and younger adults. The aim of this case series assessment was to assess the causal relationship between the AS/AQ tablet and extrapyramidal reactions in children and younger adults and to investigate the factor(s) predisposing to the adverse drug reactions. METHODS: The causal relationship of all the cases was first assessed individually using the Naranjo Probability Scale and then subjected to a case series assessment using Austin Bradford-Hill criteria. RESULTS: A total of 43 acute extrapyramidal reactions associated with the AS/AQ tablet were reported between 2012 and 16 November, 2015 to the Eritrean Pharmacovigilance Centre. The causality was found to be probable or highly probable for 33 (76.7 %) of the cases and the rest (10; 23.3 %) of the cases had a possible causal association. The extrapyramidal reactions had more or less similar clinical features in most of the cases and were characterized by abnormal involuntary contractions of muscles. The median age and body weight of the cases were 15 years and 40 kg, respectively, and 70 % of them were males. 90.7% of the reactions manifested in children and younger adults (aged <26 years). In most of the cases, reactions manifested in the third day from the start of treatment and 88.3 % of cases were hospitalized. CONCLUSION: The causal relationship between the AS/AQ tablet and extrapyramidal reactions in children and younger adults was found to be apparent and possibly owing to dose accumulation or an overdose of amodiaquine.
Authors: N D Volkow; R C Gur; G J Wang; J S Fowler; P J Moberg; Y S Ding; R Hitzemann; G Smith; J Logan Journal: Am J Psychiatry Date: 1998-03 Impact factor: 18.112
Authors: Corine Karema; Caterina I Fanello; Chantal van Overmeir; Jean-Pierre van Geertruyden; Walli van Doren; Daniel Ngamije; Umberto D'Alessandro Journal: Trans R Soc Trop Med Hyg Date: 2006-06-12 Impact factor: 2.184
Authors: Theonest K Mutabingwa; Devota Anthony; Archie Heller; Rachel Hallett; Jalal Ahmed; Chris Drakeley; Brian M Greenwood; Christopher J M Whitty Journal: Lancet Date: 2005 Apr 23-29 Impact factor: 79.321
Authors: M Adjuik; P Agnamey; A Babiker; S Borrmann; P Brasseur; M Cisse; F Cobelens; S Diallo; J F Faucher; P Garner; S Gikunda; P G Kremsner; S Krishna; B Lell; M Loolpapit; P B Matsiegui; M A Missinou; J Mwanza; F Ntoumi; P Olliaro; P Osimbo; P Rezbach; E Some; W R J Taylor Journal: Lancet Date: 2002-04-20 Impact factor: 79.321
Authors: George O Adjei; Jorgen A L Kurtzhals; Onike P Rodrigues; Michael Alifrangis; Lotte C G Hoegberg; Emmanuel D Kitcher; Ebenezer V Badoe; Roberta Lamptey; Bamenla Q Goka Journal: Malar J Date: 2008-07-11 Impact factor: 2.979
Authors: Lidia Habtemikael; Mulugeta Russom; Iyassu Bahta; Selam Mihreteab; Araia Berhane; Andreas Mårtensson; Jose Pedro Gil Journal: Pharmgenomics Pers Med Date: 2020-11-12
Authors: Serge-Brice Assi; Yapo Thomas Aba; Jean Claude Yavo; Abouo Franklin Nguessan; N'cho Bertin Tchiekoi; Koffi Moïse San; Emmanuel Bissagnéné; Stephan Duparc; Valérie Lameyre; Mea Antoine Tanoh Journal: Malar J Date: 2017-01-03 Impact factor: 2.979